Trial Profile
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms FFCD1302
- 23 Oct 2018 The study was stopped at the first stage, as reported in an abstract presented at the 43rd European Society for Medical Oncology Congress
- 26 May 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017.
- 23 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.